Pharmacogenomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, Others), By Service (Genotyping, SNP Identification, Pharmacogenetic Testing, Others), By Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, Others), By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Others), By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 9.49 Billion
CAGR (2026-2031)	10.81%
Fastest Growing Segment	PCR
Largest Market	North America
Market Size (2031)	USD 17.57 Billion

Market Overview

The Global Pharmacogenomics Market will grow from USD 9.49 Billion in 2025 to USD 17.57 Billion by 2031 at a 10.81% CAGR. Pharmacogenomics is the scientific study of how an individual's genetic attributes affect their response to medications, enabling the development of tailored therapeutic strategies that optimize efficacy and safety. The market is primarily driven by the increasing prevalence of chronic conditions such as cancer and cardiovascular diseases which necessitate precise treatment regimens to improve patient outcomes. Furthermore the urgent need to mitigate adverse drug reactions and the global shift towards personalized healthcare models are fueling the adoption of pharmacogenomic testing in clinical practice.

Despite these drivers the market faces a significant challenge regarding the inconsistent reimbursement landscape and high costs associated with genetic testing which can limit accessibility for broader patient populations. Regulatory endorsements however continue to validate the sector's trajectory. According to the Personalized Medicine Coalition in 2024 the US Food and Drug Administration approved 18 new personalized medicines representing approximately 38 percent of all newly approved therapeutic molecular entities. This data underscores the integral role of pharmacogenomics in modern drug development and its growing influence on regulatory approvals.

Key Market Drivers

Expanding applications of pharmacogenomics in oncology are fundamentally reshaping the market by necessitating precise molecular profiling for effective cancer treatment. As clinicians increasingly rely on genetic biomarkers to tailor therapeutic regimens, pharmaceutical developers are prioritizing oncology portfolios that leverage these genomic insights. This commercial shift is evident in the financial performance of major industry players who have integrated precision medicine into their core strategies to address the rising burden of cancer. According to AstraZeneca, February 2025, in the 'Annual Report and Form 20-F Information 2024', the company reported a 24 percent revenue growth in its Oncology division for the full year 2024, driven significantly by the global demand for targeted therapies. This surge underscores the direct correlation between the adoption of personalized cancer care and the sector's expanding market value.

Simultaneously, strategic collaborations between pharmaceutical companies and research organizations are accelerating the discovery of actionable genetic targets while distributing the high costs of R&D. These large-scale partnerships enable the aggregation of vast genomic datasets that would be prohibitively expensive for single entities to generate, thereby de-risking the drug development process. A prime example of this trend is the industry-wide support for major biobanking initiatives. According to UK Biobank, January 2025, in the article 'UK Biobank launches the world's largest protein study', a consortium of 14 leading biopharmaceutical companies announced funding to measure proteins in 600,000 participant samples to enhance drug discovery capabilities. Furthermore, public sector support continues to stabilize this research ecosystem; according to the National Human Genome Research Institute, in 2024, the institute maintained an enacted budget of $660.5 million to foster genomic advancements. These synergistic efforts demonstrate how cooperative models are essential for sustaining expanding market opportunities.

Download Free Sample Report

Key Market Challenges

The inconsistent reimbursement landscape and high costs associated with genetic testing act as a primary constraint on the Global Pharmacogenomics Market. Payers often lack standardized coverage policies, frequently categorizing pharmacogenomic diagnostics as investigational or non-essential. This ambiguity leads to frequent claim denials and imposes significant financial burdens on patients, which discourages them from proceeding with recommended testing. Furthermore, healthcare providers are reluctant to adopt these diagnostic tools when payment is uncertain, stifling the integration of pharmacogenomics into standard medical practice.

This economic disconnect directly hampers market growth by limiting accessibility for broader patient populations. Without reliable reimbursement, the adoption of pharmacogenomic testing remains restricted, preventing the sector from realizing its full commercial potential. According to the American Pharmacogenomics Association, in 2025, the overall reimbursement rate for pharmacogenomic testing was reported to be approximately 46 percent. This low rate of coverage highlights the severity of the financial barriers, illustrating how the prevailing reimbursement environment effectively curtails patient access and constrains the market’s expansion.

Key Market Trends

The Integration of Artificial Intelligence for Predictive Modeling is revolutionizing the market by enabling the efficient analysis of complex genomic datasets to predict drug responses with unprecedented accuracy. Unlike traditional methods, AI algorithms can identify non-linear gene-drug interactions and interpret vast libraries of clinical data, thereby enhancing the precision of pharmacological recommendations. This technological leap is generating substantial commercial value as healthcare technology companies monetize these predictive capabilities. According to Tempus AI, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company's Data and Services segment, which leverages AI to structure multimodal data, generated $241.6 million in revenue, representing a 43.2 percent year-over-year growth.

Simultaneously, the Widespread Adoption of Next-Generation Sequencing Technologies is driving market expansion through increased testing volumes and the operational scaling of diagnostic platforms. As sequencing costs stabilize and clinical utility becomes more established, diagnostic providers are processing significantly higher numbers of patient samples, validating the transition of genomic profiling from niche research to routine clinical care. This surge in utilization is quantitatively evident in the operational metrics of leading diagnostic firms. According to Guardant Health, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company reported a total of approximately 206,700 clinical tests delivered to oncologists, marking an increase of 20 percent compared to the prior year.

Segmental Insights

The Polymerase Chain Reaction (PCR) segment represents the fastest-growing technology within the global pharmacogenomics market due to its proven cost-effectiveness and high specificity. This methodology is extensively utilized for detecting known genetic variants that dictate drug metabolism, offering rapid results essential for clinical decision-making. The segment receives significant impetus from the continuous approval of PCR-based companion diagnostics by regulatory organizations such as the US FDA. Consequently, laboratories prioritize this technology for routine screening, driving its accelerated adoption over more complex alternatives for targeted genetic analysis.

Regional Insights

North America holds a dominant position in the global pharmacogenomics market due to the widespread adoption of precision medicine and substantial government funding for medical research. The region benefits from a supportive regulatory framework, notably through the U.S. Food and Drug Administration (FDA), which actively encourages the inclusion of pharmacogenomic data in drug labeling to improve patient safety. Additionally, the presence of major pharmaceutical companies and an established healthcare infrastructure supports the seamless integration of genetic testing into clinical workflows, further consolidating the region's leadership in personalized healthcare solutions.

Recent Developments

• In September 2025, Quest Diagnostics launched a new pharmacogenomic laboratory testing service designed to assist healthcare providers in understanding patients' individual genetic responses to specific drug therapies. The service covered seventeen genes and four HLA alleles with known drug associations across multiple medical specialties, including psychiatry, cardiology, and oncology. The General Manager of the company’s specialty genetics services stated that the offering was intended to guide prescription decisions and minimize adverse drug interactions. The launch utilized a partnership with InformedDNA and Coriell Life Sciences to provide personalized medication reports and clinical decision support tools.
• In January 2025, Myriad Genetics and The University of Texas MD Anderson Cancer Center announced a five-year strategic alliance focused on advancing the clinical evaluation and development of a molecular residual disease assay. The collaboration aimed to create a portfolio of studies to assess the clinical validity and utility of the assay across various cancer types, including breast, gastrointestinal, and gynecological cancers. This research initiative was established to support the development of personalized treatment plans and to monitor patient response to therapy more effectively. The alliance combined the company's diagnostic technologies with the research institution's clinical expertise.
• In November 2024, Evexia Diagnostics announced a strategic partnership with Genomind to provide clinicians with access to advanced pharmacogenetic testing services. This collaboration enabled healthcare providers to utilize a testing solution that assesses genes influencing drug metabolism, tolerability, and efficacy for a wide range of medications. The CEO of Genomind noted that the partnership was intended to help providers identify appropriate medications more efficiently, thereby reducing the trial-and-error process often associated with treating chronic conditions. The initiative aimed to enhance personalized care and improve patient outcomes by integrating precise genetic insights into clinical practice.
• In January 2024, Thermo Fisher Scientific launched the Axiom PangenomiX Array, which was described as its most ethnically diverse array to date. This new product was designed to offer optimal genetic coverage for population-scale disease studies and pharmacogenomic research. By improving the representation of human genomic variation, the array aimed to support more inclusive research related to the prevention, diagnosis, and treatment of disease. The company stated that the array included clinically relevant pharmacogenomic markers to assist researchers in building more accurate disease risk prediction models across global populations.

Key Market Players

• Abbott Laboratories, Inc.
• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• AstraZeneca Plc.
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company
• Eurofins Scientific SE
• Pacific Biosciences of California Inc.
• Qiagen N.V.
• PerkinElmer, Inc.
• Oxford Nanopore Technologies Limited
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Admera Health, LLC

By Service	By Application	By End User	By Region
Genotyping SNP Identification Pharmacogenetic Testing Others	Drug Discovery Oncology Neurology and Psychiatry Pain Management Cardiovascular Diseases Others	Hospitals & Clinics Biotechnology & Pharmaceutical Companies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pharmacogenomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pharmacogenomics Market, By Service:

• Genotyping
• SNP Identification
• Pharmacogenetic Testing
• Others

• Pharmacogenomics Market, By Application:

• Drug Discovery
• Oncology
• Neurology and Psychiatry
• Pain Management
• Cardiovascular Diseases
• Others

• Pharmacogenomics Market, By End User:

• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Others

• Pharmacogenomics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE